AxoGen develops and commercializes products used in surgical repair of peripheral nerve injuries, based on a University of Florida‑licensed enzyme treatment that enables regeneration of donated nerves. The company was co‑founded in 2002 and has more than 50 employees in Alachua. Prior to going public in 2011 it reported its products were used in roughly 400 hospitals and thousands of surgeries, including treatment for injured soldiers. AxoGen reported $4.9 million in revenue in 2011 and a record $2.01 million in Q2 2012, reflecting strong year‑over‑year growth. Management says the company will use new proceeds to expand its sales force, increase physician outreach, and develop new peripheral nerve products.

Total raised

$21M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2012